Humans with loss-of-function SLC26A3 mutations, therefore, have an estimated 40%–70% lower urinary oxalate excretion compared with healthy controls, further supporting the potential therapeutic utility of pharmacological SLC26A3 inhibition in hyperoxaluria. The gene discussed is SLC26A3; the disease is Hyperoxaluria.